Open Journal of Gastroenterology and Hepatology

Significance of nutritional treatment for patients with inflammatory bowel disease in the era of biologics

Review Article of Open Journal of Gastroenterology and Hepatology Significance of nutritional treatment for patients with inflammatory bowel disease in the era of biologics Yoshihiro Yokoyama, Tomoya Iida, Hiroshi Nakase Department of Gastroenterology and Hepatology, Sapporo Medical University, School of Medicine, Minami 1-jo Nishi 17-chome, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan, Phone: +81-11-611-2111 Fax: +81-11-611-2282 Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease (CD), is a chronic gastrointestinal tract inflammatory disorder. Although its etiology remains unknown, it has been reported that nutrition is involved in the onset of IBD. Patients with IBD often experience malnutrition due to malabsorption and increased energy requirements. Malnutrition is a serious issue for patients with IBD, especially in young people. Growth retardation characterized by delayed skeletal maturation and onset of puberty is a representative complication. In addition, immunosuppression, osteoporosis, and sarcopenia are important issues. Functional foods and diets have been known to alleviate gastrointestinal inflammation by modulating inflammatory cytokines. Furthermore, appropriate nutritional treatment has been reported to be effective on the induction and maintenance of remission in patients with IBD, especially with CD. Conversely, there are negative reports regarding the efficacy of nutritional therapy in patients with IBD. Recently, various new therapeutic agents such as biologics have emerged as key drugs in IBD treatment. In this new era, the efficacy of nutritional treatment, including combination therapy with biologics, should be reconsidered to improve the quality of life in patients with IBD. In this review, the nutritional treatment for patients with IBD is reviewed, and the latest evidence is provided. Supported by Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan (Investigation and Research for intractable Inflammatory Bowel Disease), and Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) ...


Research Article of Open Journal of Gastroenterology and Hepatology LAPAROSCOPIC SLEEVE GASTRECTOMY FOR SUPER – SUPER OBESE PATIENTS (BMI>60 KG/M2) - SINGLE INSTITUTION EXPERIENCE Ludmil MARINOV MD*1, Daniel  KRAWCZYKOWSKI MD2, Jean GUGENHEIM MD3 1Department of General Surgery, Medical Center of Brignoles, France; 2Department of General Surgery, Medical Center of Brignoles, France; 3Professor,  University hospital of Archet, Nice, France Background: According to the official WHO publications, obesity became one of the greatest public health challenges of the 21st century. In addition to causing various physical disabilities and psychological problems, excess weight drastically increases a person’s risk of developing a number of noncommunicable diseases (NCDs), including cardiovascular disease, cancer and diabetes. The risk of developing more than one of these diseases (co-morbidity) also increases with body weight gain. Obesity is already responsible for 2–8% of health costs and 10–13% of death cases and the numbers rise progressively. Objective: To perform retrospective analysis of medical records data of patients with very specific range of morbid obesity (super-super obesity- BMI >60) with laparoscopic sleeve gastrectomy and systematized preoperative criteria and morbid risk for surgical treatment. Methods: Our study includes group of 13 patients with BMI>60 kg/m2. All patients taking part in the program for treatment of morbid obesity meet the criteria of the national regulatory health system. LSG was performed following official description. We conducted a 6, 9, 12, 24, 36, 60 months follow up of patient’s status and evaluation of quality of life, and we presented the percentage of excess weight loss (EWL). Results: Evaluation of preoperative consultations and clinical examinations permitted to perform as first step Laparoscopic SG for all patients. Postoperative results were very satisfying for nine of our (69 %) patients. Three patients after interval of 10-15 months obtained complementary second step operation - duodenal switch. We found that LSG ...

Gastrointestinal manifestations in patient with Common Variable Immunodeficiency Syndrome (CVID): A Case Report

Case Report of Open Journal of Gastroenterology and Hepatology Gastrointestinal manifestations in patient with Common Variable Immunodeficiency Syndrome (CVID): A Case Report B. Christopher1, MS Ismail1, M. Kirca2, D. McNamara1 1Department of Gastroenterology, Tallaght University Hospital & Department of Clinical Medicine, Trinity College Dublin, Dublin Ireland; 2Department of Gastroenterology, Mullingar General Hospital, Mullingar, Ireland A 57 yo male with a background history of common variable Immunodeficiency syndrome (CVID) on Immunoglobulin Infusion (Kiovig) 40mg three weekly was referred for investigation of diarrhoea and follow up from previous history of colonic polyps. Colonoscopy showed an irregular looking ileocaecal valve (ICV) with an adjacent flat polyp (Paris IIa). Biopsies showed low grade dysplasia. There was also a duodenal polyp noted on gastroscopy and biopsy again showed low grade dysplasia. In light of the findings of upper and lower gastrointestinal tract polyps, a small bowel capsule endoscopy (SBCE) was arranged. This showed an irregular area of mucosa in the proximal small bowel with significant ulceration and inflammation (Figure 1). There were also multiple scattered lymphagiectasias and lymphoid hyperplasia in the distal small bowel (Figure 2). Anterograde double ballon enteroscopy (ADBE) was subsequently performed to the distal jejunum about 8 weeks after the SBCE. The duodenal polyp seen at gastroscopy was visualised during ADBE (Figure 3). In addition, two diminutive (<3mm) jejunal sessile polyps were encountered and excised (Figure 4). There was no evidence of ulcerative enteritis as seen on SBCE. The enteritis features initially visualized on the SBCE was thought to be a transient phenomenon possibly related to his CVID background. However, for completion, the distal point of enteroscopy insertion was marked and a repeat SBCE performed immediately after recovery from the ADBE. This again showed the known duodenal polyp as well as 2 further diminutive small bowel polyps and minimal distal patchy enteritis ...

Efficacy Of Potassium-Competitive Acid Blocker vs Proton Pump Inhibitor as First-Line and Second-Line Treatment for Helicobacter Pylori Eradication

Research Article of Open Journal of Gastroenterology and Hepatology Efficacy Of Potassium-Competitive Acid Blocker vs Proton Pump Inhibitor as First-Line and Second-Line Treatment for Helicobacter Pylori Eradication Dian Daniella1, Cynthia Camelia2 1 Faculty of Medicine, Atmajaya Catholic University, Jakarta 2Medistra Hospitals, South Jakarta, Indonesia Introduction: Eradication of H. pylori reduced the risk of gastric cancer by 75%, thus, its therapy with high eradication rates is needed. Nowadays, the success rate of H.pylori eradication regimen (PPI-based) has dropped to less than 75% due to clarithromycin resistance and inadequate gastric acid suppression. Vonoprazan, a Potassium-competitive acid blocker (PCAB) was released for use in first-line and second-line treatment for H.pylori eradication. It shows better acid suppression effect in acid-related disease. Aim: The aim of this study was to compare the efficacy of PCAB and PPI as first-line and second-line treatment for H. pylori eradication. Method: We search the Medline, Google Scholar and Directory of Open Access Journals (DOAJ) databases in October 2019. The study selection process was plotted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Results: In studies assessing first-line therapy, 776 patient were using PPI and 965 patient were using PCAB. In first-line therapy, PCAB has higher ITT and PP compared to PPI. According to Sue et al, in PPI group, more patient complain of diarrhea (49 vs 25; p < 0.001). In studies assessing second-line therapy, 1,069 patient were using PPI and 605 patient were using PCAB. Two studies showed no significant differences between PCAB and PPI in second-line therapy, but one study showed PCAB superiority (ITT PPI vs PCAB 85% vs 90% p=0.045; PP PPI vs PCAB 91% vs 96% p=0.008). There is no difference in adverse event between PCAB and PPI. Conclusion: In conclusion, PCAB has higher eradication rate (ITT and PP) compared to ...

Dr. Mohammed Naeem
Chair, Patient Safety Reporting/Consultant Pediatric Intensivist/ Head PICU (A)/ Assistant Professor, Dept. of Pediatrics. Ministry National Guard Health Affairs Riyadh, Saudi Arabia

Dr Toru Ishikawa
Gastroenterology, Saiseikai Niigata Daini Hospital

Dr. George Paraskevas
Associate Professor of Anatomy Orthopedic Surgeon, Department of AnatomyMedical School, Aristotle University of Thessaloniki, Post Box: 300, Post Code: 54124, Thessaloniki, Greece

Dr. Mahaboob Vali Shaik
Assistant Professor/Senior Scientist, Department of Genetics & stem cell Research, Narayana Medical College & Hospitals

Dr. Ifeadike Chigozie Ozoemena
Associate Professor, Department of Community Medicine, Faculty of Medicine, Nnamdi Azikiwe University

Dr. Eduardo de Moura GH
Professor, niversity of São Paulo School of Medicine, São Paulo, Brazil

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.Gomes, K.K.L; Lima, A.A.F. Living Style of Diabetic Patients Type.Open Journal of Gastroenterology and Hepatology, 2018, 1:5. DOI:10.28933/ojgh-2018-05-1005

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

Open Journal of Gastroenterology and Hepatology is a peer reviewed open access journal publishing research manuscripts, review articles, editorials, letters to the editor in Gastroenterology and Hepatology  (Indexing information).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

Open Journal of Gastroenterology and Hepatology LOGO1